



Company Contact:
Richard Gabriel
CEO and President
941 366-3400

-or-

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**DNAPRINT PHARMACEUTICALS TO PRESENT AT NEW YORK
LIFE SCIENCES VENTURE SUMMIT**

SARASOTA, Fla., Oct. 20, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., will present an overview of the Company’s subsidiary, DNAPrint Pharmaceuticals, at The 2006 Life Sciences Venture Summit on Wednesday, October 25, at the New Yorker Hotel, Eighth Ave. at 34th St., in New York City.

“We are pleased to have the opportunity to give influential members of the investment community as well as our peers in the life sciences sector an overview of our DNAPrint Pharmaceuticals subsidiary,” stated Company President and CEO Richard Gabriel. “We welcome their interest in the Company as we proceed with our drug development efforts.”

“DNAPrint Pharmaceuticals has a significant product pipeline, including six drug products and two diagnostic tests,” stated Dr. Gomez. “Our lead drug under development is PT-401, a Super Erythropoietin (EPO) dimer, to be used as a treatment for anemia. We are developing PT-401 in conjunction with Harvard University’s Beth Israel Deaconess Medical Center and it has been shown to be more potent, stable and longer acting than the current anemia treatment products. EPO drugs are estimated to be a \$10 billion worldwide market, and the Company expects to have PT-401 in Phase I clinical trials in the third or fourth quarter of 2007 with anticipated market approval in 2011. With this as a goal, we anticipate a cost of \$9-\$10 million to develop PT-401 for the first indication – anemia in renal failure. Our purpose in attending this summit is to seek capital for this project.”

The 2006 Life Sciences Venture Summit on October 25, presented by YoungStartup Ventures, is the premier biosciences industry gathering, connecting executives of early stage biotech, pharmaceutical, healthcare, medical device and diagnostic companies with venture capitalists, angel investors, and professional service firms, and offering the chance to share information through plenary sessions on controversial issues of the day as well as opportunities to network with leading venture capital specialists and peers in the life sciences.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The

(MORE)

Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###